Dr. Rinaldi is a founder and CEO of MedExpansion (since 2014), a consulting company, in which Alain shares his 30-year experience with biotechs developing treatments for rare and orphan diseases.

He is a graduate of the Faculty of Medicine of Saint-Etienne (France) and he holds a Master in Business management from the Institut d’Administration des Entreprises (I.A.E.) of Lyon (France).

From 1984 to 1991 Alain was working as a paediatrician in Lyon, gaining a valuable experience of clinical medicine. In 1991, he joined the pharma industry where he has been serving on different senior positions until 2013 and acquired a wide experience in Medical Affairs, Marketing and Business development of drugs. Amongst assignments, he had the opportunity to run several successful launchings of specialty drugs and to operate the strategic repositioning of a business unit of medical devices.

From 2006 to 2013 with Alexion, a US biotech company developing the orphan drug eculizumab (Soliris®), he was running the Medical Affairs department for France, Switzerland and CEE countries. He successfully built the medical foundations, implemented the clinical programs and organized the access to the treatment for patients suffering from life-threatening orphan diseases in onco-haematology, nephrology and transplantation.

Now with MedExpansion, Alain helps biotechs in immuno-oncology with projects in preclinical phases in a role of Chief Medical Officer. He provides them the global medical vision to bridge preclinical data, medical science, and clinical practices. He works out the optimal medical strategies and determines the key elements of the CDP for successful clinical phase II protocols. In this perspective, the early medical structuration of preclinical projects contributes to de-risking development and offering an investable project to investors.

Disclaimer: Any opinions expressed here are solely my own and do not express the views or opinions of my employer.